HBT1

HBT1 is an effective AMPA receptor AMPA-R potentiator. HBT1 specifically binds to the ligand-binding domain (LBD) of AMPAR and enhances receptor activity only when AMPA is present., HBT1 has almost no agonistic effect (i.e., reaching the optimal concentration, and then the efficacy decreases as the concentration continues to increase) compared with traditional AMPA-R potentiator, avoiding the bell-shaped reaction of brain-derived neurotrophic factor (BDNF) production in primary neurons. HBT1 can be applicable to a wider range of neurological and psychiatric diseases (such as depression, Alzheimer's disease, etc.) [1].

Product Specifications

CAS Number

[489408-02-8]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neuromodulation

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/hbt1.html

Purity

99.73

Solubility

10 mM in DMSO

Smiles

O=C(NC1=C(C(N)=O)C(CCCC2)=C2S1)CN3N=C(C(F)(F)F)C=C3C

Molecular Formula

C16H17F3N4O2S

Molecular Weight

386.39

Precautions

H302, H315, H319, H335

References & Citations

[1]Akiyoshi Kunugi, et al. HBT1, a Novel AMPA Receptor Potentiator with Lower Agonistic Effect, Avoided Bell-Shaped Response in In Vitro BDNF Production. J Pharmacol Exp Ther. 2018 Mar;364 (3) :377-389.